周三盘中，Apellis Pharmaceuticals（股票代码：APLS）股价大跌5.03%，引发市场关注。
此次下跌主要源于瑞穗证券分析师对该公司股票的最新评估。根据消息，瑞穗将Apellis Pharmaceuticals的目标价从30美元大幅下调至20美元，降幅达33.33%。尽管瑞穗维持了对该股的"中性"评级，但目标价的显著下调无疑打击了投资者信心。
分析人士指出，瑞穗此次下调目标价可能反映了对Apellis Pharmaceuticals未来业务发展或财务表现的担忧。然而，具体原因尚未公开。投资者正密切关注公司后续可能发布的相关声明或财报，以进一步评估其投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.